Illumina Stock Is Up 40% Since January. Should You Still Ride the Wave in 2026?

Key Takeaways for Illumina Stock as of August 2026

• Rally Recap: Illumina stock has climbed 39.9% since January, closing at $188 on Aug. 7 after a Q2 beat and a guidance raise pushed the shares to a 52-week high near $204.
• Street Catch-Up: After sitting 14% below the stock price in June, the Street’s mean target jumped to $196 by Aug. 7, now just 4% above the close.
• Ratings Split: Coverage stands at 5 buys, 4 outperforms, 6 holds, 3 underperforms, and 1 sell across 18 price targets.
• Model Target: TIKR values ILMN at $254, a 35% total return by December 2030.

Illumina stock ran on operating momentum before the Street’s targets moved. Analyze ILMN’s full ratings history and target trend on TIKR for free →

Why Illumina Stock’s 40% Rally Since January Finally Has Wall Street Playing Catch-Up

Illumina (ILMN) stock has returned 40% since the start of the year, a 75.5% annualized pace that carried the shares from the $130s in January to a 52-week high of $204 in early August, before settling at $188 on Aug. 7. The climb wasn’t smooth. Illumina stock spent February through May stuck between $120 and $145, and even the breakout months carried scars: Danaher’s July 21 guidance cut knocked Illumina and its diagnostics peers down 2% to 4% in a single session, a reminder the group still trades as a pack.

The real turn came nine days later. Illumina reported second-quarter revenue of $1.16 billion on July 30, up 9.5% and ahead of the $1.13 billion analysts expected, while adjusted earnings of $1.31 a share beat the Street’s $1.23 estimate. Management raised full-year revenue guidance to $4.60 billion to $4.64 billion from $4.52 billion to $4.62 billion and lifted adjusted EPS guidance to $5.30 to $5.40 from $5.15 to $5.30, with rest-of-world organic growth now expected above 5%, up from a prior 2% to 4% range. The company placed more than 95 NovaSeq X sequencers in the quarter, extending a run of elevated instrument sales it has kept up for three straight quarters.

That durability was the question on the call. Asked whether 2027 growth could beat the high single digits management has guided to, CEO Jacob Thaysen pushed back on the idea that clinical demand would fade: “Talking about the clinical cliff, I agree, it’s not a cliff. It’s a wave, and we are surfing it.” A rally built on one strong placement quarter would deserve skepticism. A rally built on an installed base that keeps pulling through consumables does not, and Thaysen’s answer is the case for the latter.

Illumina stock got another tailwind the next day, when a Reuters report on S&P 500 index changes named Illumina, then the largest constituent of the S&P MidCap 400, as a candidate for promotion if the index committee handles Electronic Arts’ exit as part of a broader reshuffle.

Nothing has been confirmed since. The stock has since given back some of its gain, falling from the $204 peak to $188 as director Keith Meister disclosed the sale of 739,127 shares for $148.86 million on Aug. 4 and Aug. 5. None of that changes the core story: Illumina stock re-rated because the clinical sequencing business accelerated, and the Street had not caught up yet.

Illumina stock’s rally forced a market that had priced in stagnation to reprice a business that was quietly accelerating. Get the same guidance, coverage, and target data on ILMN on TIKR for free

Illumina Stock’s Ratings Split Shows a Street That Waited Until the Print to Move

Coverage on Illumina stock stood at 5 buys, 4 outperforms, 6 holds, 3 underperforms, and 1 sell as of Aug. 7, spread across 18 analysts publishing price targets. The mean target of $196 sits 4% above the $188 close, a gap that has nearly closed after months of the Street lagging the stock.

That gap used to run the other way. The mean target sat 14% below Illumina’s close as of June 28, when the stock had already rallied to $177 and analysts were still anchored near $152. Coverage has also thinned, falling from 23 analysts issuing targets in mid-2025 to 18 now, even as the mean target itself jumped 29% in the six weeks after the Q2 print. Fewer analysts, but a much higher number from the ones left, points to a Street revising sharply rather than gradually.

The pattern lines up with Section 1’s argument. Illumina stock ran on operating momentum through July, and the target moves only followed once the guidance raise made the clinical growth case explicit. Ratings themselves have gotten more mixed even as targets rose: buy-rated analysts fell from 12 of 25 rated in mid-2025 to 9 of 19 now, while underperform and sell views doubled over the same stretch.

TIKR Values Illumina Stock at $254, Pricing In Sustained Clinical Growth

TIKR’s mid-case model values Illumina at $254 by December 2030, implying a 35% total return from the current price of $188, or 7% annualized over 4.4 years.

That return sits below the stock’s own trailing pace. Illumina shares returned 40% in the past seven months alone, a run the model does not expect to repeat, positioning the mid-case target as a more measured outcome than the sector-beating momentum investors have collected since January.

The case for reaching it rests on the same clinical conversion story the Street just started pricing in. With 78% of clinical sequencing volume already running on NovaSeq X and mid-teens clinical consumables growth guided for 2026, the installed base Illumina built through elevated placements this year keeps pulling through revenue well past the point where instrument sales themselves decelerate.

The rerating shows up in the multiple, not just the estimates. Illumina’s forward price-to-earnings ratio sits at 33x, up from roughly 20 times last October and above its trailing mean of 26. TIKR’s mid-case return assumes that multiple settles back toward its own average even as clinical earnings keep compounding.

Illumina stock trades near TIKR’s estimate of fair value already reached by 2030. See the full model behind the $254 target on ILMN on TIKR for free →

Should You Invest in Illumina, Inc.?

The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.

Pull up Illumina, Inc. stock and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.

You can build a free watchlist to track Illumina, Inc. alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.

Access Professional Tools to Analyze ILMN stock on TIKR for Free →

Looking for New Opportunities?

Disclaimer:

Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!